Stock
Quantum Biopharma Ltd. Class B Subordinate Voting Shares QNTM
Overview
QNTM market data
Price History
QNTM price chart · 1M
- O
- 3.14
- H
- 3.14
- L
- 3.09
- C
- 3.13
- Vol
- 1,310.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $3.14
- Previous Close
- $3.09
- Day High
- $3.14
- Day Low
- $3.09
- 52 Week High
- $10.80
- 52 Week Low
- $2.70
- 7 Day Return
- -9.41%
- 30 Day Return
- +1.13%
- 90 Day Return
- -54.37%
- 1 Year Return
- -44.75%
- Daily Notional Volume
- $4.1K Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$7.97 Diluted earnings per share over the trailing twelve months.
- Beta
- 5.36 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -9,078.9% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $2.85 – $28.59 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $30.7M · P/S 132.69.
Company News
Quantum Biopharma shares are trading higher after the company announced it received FDA approval to proceed with its Lucid-MS Phase 2 clinical trial in progressive multiple sclerosis.Benzinga · Aug 14, 2026, 6:37 PM
Quantum BioPharma Says FDA Cleared IND For Lucid-MS Phase 2 Trial In Progressive Multiple Sclerosis; Reports Cash Runway To At Least October 2027Benzinga · Aug 14, 2026, 11:12 AM
EXCLUSIVE: Quantum BioPharma Achieves Major Milestone With FDA Clearance for Multiple Sclerosis TrialBenzinga · Aug 10, 2026, 10:31 AM
EXCLUSIVE: FDA Approves Quantum BioPharma's Lucid-MS Phase 2 Trial of Patented First-in-Class Neuroprotective Therapy Targeting Demyelination For Progressive Multiple SclerosisBenzinga · Aug 10, 2026, 10:30 AM
Quantum BioPharma Announces Closing of Debt SettlementGlobenewswire Inc · Jul 30, 2026, 11:00 AM
Reported Earlier, Quantum BioPharma Approves Debt Settlement Of C$123,487.43 Via Class B Shares At Deemed Price Of C$4.26 Or LowerBenzinga · Jul 21, 2026, 6:53 AM
Quantum BioPharma Announces Intention to Settle DebtGlobenewswire Inc · Jul 20, 2026, 11:30 PM
Trading Halt: Halt status updated at 7:05:00 AM ET: Quotation Resumption: News and Resumption TimesBenzinga · Jun 2, 2026, 11:05 AM
Trading Halt: Halted at 7:25:00 p.m. ET - Trading Halt: Halt News PendingBenzinga · Jun 1, 2026, 11:25 PM